Review
Copyright ©The Author(s) 2020.
World J Clin Cases. Sep 26, 2020; 8(18): 3942-3955
Published online Sep 26, 2020. doi: 10.12998/wjcc.v8.i18.3942
Table 1 Definitions of common variable immunodeficiency proposed by Ameratunga et al[80], European Society of Immune Deficiencies[12] and International Consensus Document[55]
Ameratunga et al[80] 2013
Must meet all major criteria:
Hypogammaglobulinemia IgG < 5 g/L
No other cause identified for immune defect
Age > 4 yr
Sequelae directly attributable to immune system failure (ISF) (1 or more):
Recurrent, severe or unusual infections
Poor response to antibiotics
Breakthrough infections in spite of prophylactic antibiotics
Infections in spite of appropriate vaccination, e.g., human papilloma virus disease
Bronchiectasis and/or chronic sinus disease
Inflammatory disorders or autoimmunity
Supportive laboratory evidence (3 or more criteria):
Concomitant reduction or deficiency of IgA (< 0.8 g/L) and/or IgM (0.4 g/L)
Presence of B cells but reduced memory B cell subsets and/or
Increased CD21 low subsets by flow cytometry
IgG3 deficiency (< 0.2 g/L)
Impaired vaccine responses compared with age-matched controls
Transient vaccine responses compared with age-matched controls
Absent isohemagglutinins (if not blood group AB)
Serological evidence of significant autoimmunity, e.g., Coombes test
Sequence variations of genes predisposing to CVID, e.g., TNFRSF13B/TACI, TNFRSF13C/BAFFR and MSH5
Presence of relatively specific histological markers of CVID (not required for diagnosis but presence increases diagnostic certainty, in the context of category A and B criteria):
Lymphoid interstitial pneumonitis
Granulomatous disorder
Nodular regenerative hyperplasia of the liver
Nodular lymphoid hyperplasia of the gut
Absence of plasma cells on gut biopsy
ESID 2014
At least one of the following:
Increased susceptibility to infection
Autoimmune manifestations
Granulomatous disease
Unexplained polyclonal proliferation
Affected family member with antibody deficiency
AND
Marked decrease of IgG and marked decrease of IgA with or without low IgM levels (measured at least twice; < 2SD of the normal levels for their age)
AND
At least one of the following:
Poor antibody response to vaccines (and/or absent isohemaglutinins); i.e., absence of protective levels despite vaccination were defined
Low switched memory B cells (< 70% of age-related normal value)
AND
Secondary causes of hypogammaglobulinemia has been excluded:
AND
Diagnosis is established after the fourth of year of life (but symptoms can be present earlier)
AND
No evidence of profound T-cell deficiency, defined as 2 of the following (y: Year of life):
CD4 numbers/microliter:
2-6 yr < 300, 6-12 yr < 250, 12 yr < 200
% naive CD4:
2-6 yr < 25%, 6-12 yr < 20%, 12 yr < 10%
T cell proliferation absent
ICON 2016
At least 1 of the characteristic clinical manifestations: Infection, autoimmunity, lymphoproliferation
OR
Asymptomatic individuals, especially in familial cases who fulfill criteria 2 to 5, hypogammaglobulinemia should be defined according to the age adjusted reference range for the laboratory in which the measurement is performed
The IgG level must be repeatedly low in at least 2 measurements more than 3 wk apart in all patients. may be omitted if the level is very low < 100-300 mg/dL depending on age, and other characteristic features are present, IgA or IgM level must also be low
There must be a demonstrable impairment of response to at least 1 type of antigen (TD or TI), at the discretion of the practitioner, specific antibody measurement may be dispensed with if all other criteria are satisfied and if the delay incurred by prevaccination and postvaccination antibody measurement is thought to be deleterious to the patient’s health
Other causes of hypogammaglobulinemia must be excluded
Genetic studies to investigate monogenic forms of CVID or for disease-modifying polymorphisms are not generally required for diagnosis and management in most of the patients, especially those who present with infections only without immune dysregulation, autoimmunity, malignancy, or other complications